NCT01788384已完成3 期
A Multicenter, Double-blind, Randomized, Vehicle-controlled, Parallel-group Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel and Acanya® 1.2%/2.5% and Both Active Treatments to Vehicle Control for Treating Acne Vulgaris
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 708
- 主要终点
- The evaluation of the primary endpoint will be based on the mean percent changes from baseline to week 12 in the inflammatory (papules and pustules) lesion counts and in the non-inflammatory (comedones) lesion counts.
研究概览
简要总结
Acanya (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel marketed by Valeant Pharmaceuticals, North America, is a safe and effective topical therapy used for the treatment of acne vulgaris.
详细描述
Watson Laboratories, Inc. has developed a generic formulation of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%,and the current study is designed to evaluate the safety and efficacy of this formulation to determine if it is bioequivalent to Acanya.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 40 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Healthy male or non pregnant female
- •≥ 12 and ≤ 40 years
- •Diagnosis of acne vulgaris (acne)
- •>18 years and provide written informed consent
- •Ages 12 to 17 and provide written assent and written informed consent from patient's legal representative
- •Must sign a HIPAA authorization
- •Minimum ≥ 25 non-inflammatory lesions
- •≥ 20 inflammatory lesions
- •≤ 2 nodulocystic lesions on the face
- •Acne of severity grade 2, 3, or 4 -Investigator's Global Assessment (IGA)
- •Refrain from all other topical acne medications or antibiotics during the 12-week treatment period except Investigational Product
- •All Female patients with a negative urine pregnancy test who use birth control from the study start to 30 days after the last administration of study drug
- •All male patients who use birth control with their partners, from the study start to 30 days after the last administration of study drug. Abstinence is acceptable. Female partners should use birth control
- •Must be willing and able to understand and comply with the protocol requirements and required study visits
- •In good health
- •Free from any clinically significant disease
- •Must have used the same brands/types of make-up for a minimum period of 14 days prior to study entry and must agree to use the same make-up, brand/type and maintain the same frequency of use throughout the study
排除标准
- •Female patients who are pregnant, nursing or planning to become pregnant during study
- •History or presence of Crohn's disease, ulcerative colitis, regional enteritis, or antibiotic-associated colitis
- •Hypersensitivity or allergy to benzoyl peroxide, clindamycin and/or any of the study medication ingredients
- •Presence of any skin condition that would interfere with the diagnosis or assessment
- •Excessive facial hair
- •Wax epilation of the face within 14 days prior
- •Used oral retinoids or therapeutic vitamin A supplements of >10,000 units/day (multivitamins are allowed) within 6 months prior to or during the study
- •Estrogens or oral contraceptives for <3 months prior to baseline; Use of such therapy must remain constant throughout the study
- •Cryodestruction, chemodestruction, dermabrasion, photodynamic therapy, acne surgery, intralesional steroids, X-ray therapy procedures performed on the face within 1 month prior to or during the study
- •Any systemic (steroids, antibiotics treatment for acne, anti-inflammatory agents) treatments within 1 month prior to baseline or during the study
- •Any (topical steroids, topical retinoids, α-hydroxy/glycolic acid, benzoyl peroxide, topical anti-inflammatory agents, topical antibiotics) treatments within 2 weeks prior to baseline or during the study:
- •Intend to use Spironolactone
- •Intend to use tanning booths, sunbathing, or excessive exposure to the sun
- •Radiation therapy and/or anti-neoplastic agents within 90 days prior to baseline
- •Unstable clinically significant medical disorders or life-threatening diseases
- •On-going malignancies requiring systemic treatment
- •Any malignancy of the facial area skin
- •Engage in activities that involve excessive or prolonged exposure to sunlight or weather extremes
- •Consume excessive amounts of alcohol or use drugs of abuse
- •Participation in an investigational drug study within 30 days prior
- •Are participating in non-treatment studies such as observational studies or registry studies can be considered for inclusion
- •Previously enrolled in this study
- •Laser therapy, electrodessication and phototherapy to the facial area within 180 days prior to study entry
- •Cosmetic procedures which may affect the efficacy and safety profile of the study drug within 14 days prior to study entry
- •Currently have or have recently had bacterial folliculitis on the face
研究组 & 干预措施
Acanya
Active Comparator
Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel (Valeant Pharmaceuticals, North America)
干预措施: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Drug)
Clindamycin Phosphate / Benzoyl Peroxide
Experimental
Clindamycin Phosphate / Benzoyl Peroxide Gel, 1.2%/2.5%
干预措施: Clindamycin Phosphate / Benzoyl Peroxide Gel (Drug)
Vehicle Gel
Placebo Comparator
Placebo (Vehicle Gel)of the test product (Watson Laboratories, Inc.)
干预措施: Placebo (Vehicle Gel) (Drug)
结局指标
主要结局
The evaluation of the primary endpoint will be based on the mean percent changes from baseline to week 12 in the inflammatory (papules and pustules) lesion counts and in the non-inflammatory (comedones) lesion counts.
时间窗: Week 12
次要结局
- The proportion of subjects with a clinical response of "success" at Week 12 using IGA.(12 Weeks)
研究者
相似试验
已完成
3 期
Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne VulgarisAcne VulgarisNCT02616614Actavis Inc.862
已完成
不适用
A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne VulgarisAcne VulgarisNCT01501799Actavis Mid-Atlantic LLC885
已完成
1 期
W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy VolunteersAcne VulgarisNCT01929278Stiefel, a GSK Company37
已完成
4 期
Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne VulgarisAcne VulgarisNCT00160394Stiefel, a GSK Company130
已完成
2 期
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy PatientsDuchenne Muscular DystrophyNCT01396239Sarepta Therapeutics, Inc.12